Recent Updates
Recently added Catalysts
FDMT Positive Sentiment

David Kirn, Co-Founder & CEO, named a 2024 PharmaVoice 100 honoree in the Standout Leaders category

Key Takeaway: David Kirn, Co-Founder and CEO of FDMT, has been named a 2024 PharmaVoice 100 honoree in the Standout Leaders category. This recognition celebrates leaders who are reshaping the pharmaceutical industry through innovation and significant contributions. The PharmaVoice 100 list highlights various professionals across multiple categories, showcasing the ongoing transformation within the sector.
Price reaction · baseline $9.25 (2024-10-09T14:08:00.000Z) · hit during market hours · clean, no other FDMT news in the window
day 0 close · peak
-2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • David Kirn recognized as a leader in the pharma industry.
  • PharmaVoice 100 honors transformative figures in healthcare.
  • Recognition highlights significant advancements in pharmaceuticals.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration

Full Press Release Details

Industry leaders reshaping the pharma world.
The pharma industry is always transforming. Scientific and business advances build on achievements from the past, and major breakthroughs reshape the market. Behind the many changes of the last year are the leaders that drive that transformation, and their advances have been prolific.
GLP-1 agonists once primarily used for diabetes shifted to obesity and found runaway success. Advances in gene therapies paved the way to the approval of the first gene editing CRISPR drug. Leaps in oncology such as CAR-T cell therapies are improving with off-the-shelf treatments that could open the manufacturing bottleneck. Emerging AI and machine learning tools are increasingly impacting a wide array of pharma operations.
In the backdrop of this forward momentum, the industry is adapting to the market’s shifting landscape — the biotech sector’s recovery, new pricing regulations brought by the Inflation Reduction Act and the ongoing push to move the needle on equity goals have all shaped that ecosystem.
This year’s PharmaVoice 100 encompasses the industry’s ongoing revolutions. Our list salutes leaders who are not only navigating these changes, but at times, forging new paths for others to follow.
These are some of the industry’s most inspiring professionals, honored in 10 distinct categories: Standout Leaders, Clinical Trial Pros, Trailblazers, Patient Champions, Biotech Pathfinders, Cancer Care Visionaries, Cardiometabolic All-stars, Cell and Gene Therapy Pioneers, Rare Disease Warriors, and Tech and AI Wizards.
Here are this year’s PharmaVoice 100 honorees.
Editor’s note: We received hundreds of submissions this year and making final cuts wasn’t easy. Thank you so much to the many leaders across the industry who put forth the names of pharma’s inspiring individuals.
Starting in 2025, we are no longer running the PharmaVoice 100. Instead, we’re featuring standout leaders all year round in a range of ongoing series. Please submit your nominations for leaders you think we should feature anytime.
Find an honoree

Categories

Companies

Honorees

Frequently Asked Questions

Who is David Kirn?

David Kirn is the Co-Founder and CEO of FDMT, recognized for his leadership in pharma.

What is the PharmaVoice 100?

The PharmaVoice 100 honors leaders in the pharmaceutical industry for their contributions.

What category did Kirn win in?

David Kirn was honored in the Standout Leaders category of the PharmaVoice 100.

When will PharmaVoice 100 be discontinued?

Starting in 2025, the PharmaVoice 100 will no longer be published.

Last updated: Oct 9, 2024